American Heart Journal
Volume 148, Issue 5 , Pages 795-802, November 2004

Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: Insights from GUSTO I Economics and Quality of Life substudy

  • Alejandro Barbagelata, MD

      Affiliations

    • Hospital Italiano, Buenos Aires, Argentina
  • ,
  • Robert M. Califf, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
  • ,
  • Elena B. Sgarbossa, MD

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, USA
  • ,
  • David Knight, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
  • ,
  • Daniel B. Mark, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
  • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
  • ,
  • Paul W. Armstrong, MD

      Affiliations

    • University of Alberta, Edmonton, Alberta, Canada
  • ,
  • Marcelo Elizari, MD

      Affiliations

    • Hospital Ramos Mejia, Buenos Aires, Argentina
  • ,
  • Yochai Birnbaum, MD

      Affiliations

    • University of Texas Medical Branch, Galveston, Tex, USA
  • ,
  • Liliana R. Grinfeld, MD

      Affiliations

    • Hospital Italiano, Buenos Aires, Argentina
  • ,
  • E.Magnus Ohman, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
  • ,
  • Galen S. Wagner, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
    • Corresponding Author InformationReprint requests: Galen S. Wagner, MD, Duke University Medical Center, 2400 Pratt St, Rm 0306, Durham, NC 7705, USA.
  • ,
  • GUSTO-1 Investigators

Received 13 October 2003; accepted 30 April 2004.

Abstract 

Background

Current methods for risk stratification after acute myocardial infarction (MI) include several noninvasive studies. In this cost-containment era, the development of low-cost means should be encouraged. We assessed the ability of an electrocardiogram (ECG) MI-sizing score to predict outcomes in patients enrolled in the Economics and Quality of Life (EQOL) sub study of the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries –I (GUSTO-I) trial.

Methods

We classified patients by electrocardiographic Selvester QRS score at hospital discharge: those with a score 0–9 versus ≥10. Endpoints were 30-day and 1-year mortality, resource use, and quality-of-life measures.

Results

Patients with a QRS score <10 were well-matched with those with QRS score ≥10 with the exception of a trend to more anterior MI in the higher scored group. Patients with QRS score ≥10 had increased risk of death at 30-days (8.9% vs. 2.9% P < .001), and this difference persisted at 1 year (12.6% vs. 5.4%, P = .001). Recurrent chest pain, use of angiography, and angioplasty were similar during follow-up. However, there was a trend toward less coronary bypass surgery in patients with a QRS score ≥10. Readmission rates were higher at 30 days but similar at 1 year.

Conclusions

Stratification of patients after acute MI by a simple measure of MI size identifies populations with different long-term prognoses; patients with a QRS score ≥10 (approximately 30% of the left ventricle infarcted) at discharge have poorer outcomes in both the short- and long-term. The standard 12-lead ECG provides a simple, economical means of risk stratification at discharge.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from Bayer (New York, NY), Genentech, Inc. (South San Francisco, Calif), CIBA-Corning (Medfor, Mass), ICI Pharmaceuticals (Wilmington, Del), and Sanofi Pharmaceuticals (Paris, France).

PII: S0002-8703(04)00259-5

doi:10.1016/j.ahj.2004.04.046

American Heart Journal
Volume 148, Issue 5 , Pages 795-802, November 2004